Trial · NCT04247594
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Treatment-emergent Adverse Events (AEs) | Voxelotor 1500 mg | Sickle cell disease (SCD) related TEAE | 5 | Participants | |
| Treatment-emergent Adverse Events (AEs) | Voxelotor 2000 mg | Sickle cell disease (SCD) related TEAE | 1 | Participants | |
| Treatment-emergent Adverse Events (AEs) | Voxelotor 2500 mg | Sickle cell disease (SCD) related TEAE | 1 | Participants | |
| Treatment-emergent Adverse Events (AEs) | Voxelotor 3000 mg | Sickle cell disease (SCD) related TEAE | 0 | Participants | |
| Treatment-emergent Adverse Events (AEs) | Voxelotor 1500 mg | Non-SCD related TEAE | 6 | Participants | |
| Treatment-emergent Adverse Events (AEs) | Voxelotor 2000 mg | Non-SCD related TEAE | 4 | Participants | |
| Treatment-emergent Adverse Events (AEs) | Voxelotor 2500 mg | Non-SCD related TEAE | 2 | Participants | |
| Treatment-emergent Adverse Events (AEs) | Voxelotor 3000 mg | Non-SCD related TEAE | 1 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Hb, Unconjugated Bilirubin, % Reticulocyte, Absolute Reticulocyte, and Lactate Dehydrogenase [LDH] | Voxelotor 1500 mg | 0 | Participants | ||
| Number of Participants With Clinically Significant Abnormalities in Hb, Unconjugated Bilirubin, % Reticulocyte, Absolute Reticulocyte, and Lactate Dehydrogenase [LDH] | Voxelotor 2000 mg | 0 | Participants | ||
| Number of Participants With Clinically Significant Abnormalities in Hb, Unconjugated Bilirubin, % Reticulocyte, Absolute Reticulocyte, and Lactate Dehydrogenase [LDH] | Voxelotor 2500 mg | 0 | Participants | ||
| Number of Participants With Clinically Significant Abnormalities in Hb, Unconjugated Bilirubin, % Reticulocyte, Absolute Reticulocyte, and Lactate Dehydrogenase [LDH] | Voxelotor 3000 mg | 0 | Participants | ||
| Number of Participants With an Hb Increase > 1 g/dL Compared to Baseline | Open Label | 0 | Participants | ||
| Incidence Rate of VOCs | Open Label | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04247594/results